Catalyst Pharmaceuticals (NASDAQ:CPRX) Sets New 1-Year High at $21.10

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) hit a new 52-week high during trading on Thursday . The stock traded as high as $21.10 and last traded at $20.98, with a volume of 78838 shares traded. The stock had previously closed at $20.43.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. Truist Financial increased their price target on shares of Catalyst Pharmaceuticals from $25.00 to $30.00 and gave the company a “buy” rating in a report on Friday, August 9th. Oppenheimer reiterated an “outperform” rating and set a $29.00 price target on shares of Catalyst Pharmaceuticals in a research report on Thursday, June 6th. Citigroup upped their price target on Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a “buy” rating in a report on Friday, August 9th. HC Wainwright lifted their price target on Catalyst Pharmaceuticals from $26.00 to $30.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Finally, StockNews.com raised shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 9th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $29.50.

Catalyst Pharmaceuticals Stock Down 2.6 %

The business’s fifty day moving average price is $18.90 and its 200 day moving average price is $16.81. The firm has a market capitalization of $2.46 billion, a PE ratio of 38.50, a P/E/G ratio of 3.10 and a beta of 0.75.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last released its earnings results on Wednesday, August 7th. The biopharmaceutical company reported $0.52 EPS for the quarter, topping the consensus estimate of $0.39 by $0.13. The firm had revenue of $122.71 million during the quarter, compared to analysts’ expectations of $111.76 million. Catalyst Pharmaceuticals had a net margin of 15.69% and a return on equity of 27.77%. As a group, sell-side analysts forecast that Catalyst Pharmaceuticals, Inc. will post 1.82 earnings per share for the current fiscal year.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other news, insider Steve Miller sold 150,000 shares of the stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $20.35, for a total transaction of $3,052,500.00. Following the transaction, the insider now directly owns 675,124 shares in the company, valued at approximately $13,738,773.40. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, insider Steve Miller sold 150,000 shares of the company’s stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $20.35, for a total transaction of $3,052,500.00. Following the completion of the sale, the insider now directly owns 675,124 shares in the company, valued at approximately $13,738,773.40. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Carmen Jeffrey Del sold 36,058 shares of Catalyst Pharmaceuticals stock in a transaction on Friday, August 9th. The shares were sold at an average price of $18.42, for a total value of $664,188.36. Following the completion of the transaction, the insider now owns 12,369 shares in the company, valued at approximately $227,836.98. The disclosure for this sale can be found here. Insiders sold 201,058 shares of company stock worth $4,018,188 in the last 90 days. 11.00% of the stock is owned by company insiders.

Institutional Trading of Catalyst Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Catalyst Pharmaceuticals during the second quarter worth approximately $153,000. PVG Asset Management Corp acquired a new position in shares of Catalyst Pharmaceuticals during the 2nd quarter valued at $183,000. Point72 Asset Management L.P. boosted its position in Catalyst Pharmaceuticals by 47.9% during the 2nd quarter. Point72 Asset Management L.P. now owns 618,296 shares of the biopharmaceutical company’s stock worth $9,577,000 after purchasing an additional 200,370 shares during the period. Quarry LP increased its holdings in Catalyst Pharmaceuticals by 170.0% in the 2nd quarter. Quarry LP now owns 16,334 shares of the biopharmaceutical company’s stock valued at $253,000 after purchasing an additional 10,284 shares in the last quarter. Finally, Algert Global LLC purchased a new position in Catalyst Pharmaceuticals in the second quarter valued at about $165,000. Institutional investors and hedge funds own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.